SURAPOL ISSARAGRISIL, M.D.; ANONG PAINKIJAGUM, M.D., Ph.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Over the past decade, clinical and laboratory evidence has suggested that aplastic anemia is, in some patients, due to an "autoimmune mechanism," and interest has focused on the possibility of treating patients with immunosuppressive therapy (1). Antithymocyte globulin has been considered effective therapy for aplastic anemia in randomized control studies (2), but it is expensive and causes complications. Long-term bolus doses of methylprednisolone have been shown to induce hematologic recovery in such patients (3, 4). In our experience long-term treatment with methylprednisolone is usually associated with high morbidity and mortality due to infections. To avoid this complication,
ISSARAGRISIL S, PAINKIJAGUM A. Methylprednisolone and Aplastic Anemia. Ann Intern Med. ;103:964. doi: 10.7326/0003-4819-103-6-964_1
Download citation file:
Published: Ann Intern Med. 1985;103(6_Part_1):964.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use